Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BGBIO.OL
- Price
- 1.56
- Stock movement down
- -0.08 (-5.02%)
- Company name
- Bergenbio ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 61.14M
- Ent value
- -95.77M
- Price/Sales
- 117.35
- Price/Book
- 0.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.48%
- 1 year return
- -91.01%
- 3 year return
- -81.22%
- 5 year return
- -61.15%
- 10 year return
- -
Last updated: 2025-04-05
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
BGBIO.OL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 117.35 |
| Price to Book | 0.35 |
| EV to Sales | -183.83 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 39.09M |
| EPS (TTM) | -3.98 |
| FCF per share (TTM) | -4.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 521.00K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -162.16M |
| Net income (TTM) | -155.41M |
| EPS (TTM) | -3.98 |
| EPS (1y forward) | -5.02 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -31124.18% |
| Profit margin (TTM) | -29828.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 200.12M |
| Net receivables | 0.00 |
| Total current assets | 218.25M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 218.47M |
| Accounts payable | 8.62M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 43.21M |
| Total liabilities | 43.21M |
| Shareholder's equity | 175.26M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -166.76M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -166.76M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -88.67% |
| Return on Assets | -71.13% |
| Return on Invested Capital | -88.67% |
| Cash Return on Invested Capital | -95.15% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.65 |
| Daily high | 1.68 |
| Daily low | 1.52 |
| Daily Volume | 539K |
| All-time high | 586.68 |
| 1y analyst estimate | 20.00 |
| Beta | 1.64 |
| EPS (TTM) | -3.98 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 May 2025 |
Downside potential
Loading...
Downside potential data
| BGBIO.OL | S&P500 | |
| Current price drop from All-time high | -99.73% | -17.56% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 11 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -60.41% | -11.07% |
| Avg time to new high | 118 days | 12 days |
| Max time to new high | 1722 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
61.14M
Marketcap category
Small-cap
Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
Employees
15
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been ...
January 7, 2025
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø...
November 20, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quar...
November 13, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from th...
October 7, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quart...
August 21, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a ...
August 20, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and S...
July 29, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quar...
May 29, 2024
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clin...
May 28, 2024